نتایج جستجو برای: oral ribavirin

تعداد نتایج: 257921  

Journal: :Annals of internal medicine 2013
Mark S Sulkowski Kenneth E Sherman Douglas T Dieterich Mohammad Bsharat Lisa Mahnke Jürgen K Rockstroh Shahin Gharakhanian Scott McCallister Joshua Henshaw Pierre-Marie Girard Bambang Adiwijaya Varun Garg Raymond A Rubin Nathalie Adda Vincent Soriano

BACKGROUND Telaprevir (TVR) plus peginterferon-α2a (PEG-IFN-α2a) and ribavirin substantially increases treatment efficacy for genotype 1 chronic hepatitis C virus (HCV) infection versus PEG-IFN-α2a-ribavirin alone. Its safety and efficacy in patients with HCV and HIV-1 are unknown. OBJECTIVE To assess the safety and efficacy of TVR plus PEG-IFN-α2a-ribavirin in patients with genotype 1 HCV an...

2009
Pietro Lampertico Alessio Aghemo Mauro Viganò Massimo Colombo

One year of interferon therapy inhibits HBV replication in one third of the patients whereas long-term administration of oral nucleos(t)ide analogues is efficient in most of them, as long as early treatment adaptation in patients with partial virological response and resistance is provided. Following the demonstration of a more potent antiviral effect in terms of sustained virological response ...

2014
Christian M Lange Ira M Jacobson Charles M Rice Stefan Zeuzem

Opportunities to treat infection with hepatitis C virus (HCV) are evolving rapidly. From the introduction of interferon‐α monotherapy in 1992 to the approval of telaprevir‐ and boceprevir‐based triple therapies with pegylated interferon‐α and ribavirin in 2011, the chances of curing patients infected with HCV genotype 1 have improved from <10% to approximately 70%. Significant further improveme...

Journal: :Swiss medical weekly 2003
Barbara S E August-Jörg Jan Borovicka Jean-François Dufour Jean-Jacques Gonvers Samuel Henz Rudolf Hermann Christa Meyenberger Manfred Weitz Eberhard L Renner

BACKGROUND/AIM Roughly 50% of patients with chronic hepatitis C, who relapsed after a previous monotherapy with interferon alpha, will respond in a sustained fashion to 24 weeks of re-therapy with the combination of interferon alpha plus ribavirin. Whether prolonging treatment duration to 48 weeks will further increase sustained response rates remains ill defined. In this randomised controlled ...

Journal: :BMC Gastroenterology 2003
Bart J Veldt Johannes T Brouwer Michael Adler Frederik Nevens Peter Michielsen Jean Delwaide Bettina E Hansen Solko W Schalm

BACKGROUND Evidence based medicine depends on unbiased selection of completed randomized controlled trials. For completeness it is important to publish all trials. This report describes the first large randomised controlled trial where combination therapy was compared to placebo therapy and to ribavirin monotherapy, which has not been published until now. METHODS One hundred and twenty one pa...

Journal: :The New England journal of medicine 2014
Nassim Kamar Jacques Izopet Simona Tripon Michael Bismuth Sophie Hillaire Jérôme Dumortier Sylvie Radenne Audrey Coilly Valérie Garrigue Louis D'Alteroche Matthias Buchler Lionel Couzi Pascal Lebray Sebastien Dharancy Anne Minello Maryvonne Hourmant Anne-Marie Roque-Afonso Florence Abravanel Stanislas Pol Lionel Rostaing Vincent Mallet

BACKGROUND There is no established therapy for hepatitis E virus (HEV) infection. The aim of this retrospective, multicenter case series was to assess the effects of ribavirin as monotherapy for solid-organ transplant recipients with prolonged HEV viremia. METHODS We examined the records of 59 patients who had received a solid-organ transplant (37 kidney-transplant recipients, 10 liver-transp...

Journal: :Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2003
Annette Bruchfeld Karin Lindahl Lars Ståhle Magnus Söderberg Robert Schvarcz

BACKGROUND Hepatitis C virus (HCV) infection is associated with renal manifestations, such as membranoproliferative glomerulonephritis (MPGN) with or without cryoglobulinaemia, membranous glomerulonephritis (MGN) and focal segmental glomerulosclerosis (FSGS). Standard treatment for HCV is interferon and ribavirin, but in renal insufficiency ribavirin has been contraindicated due to fear of side...

2013
Ana M. Ortega-Prieto Julie Sheldon Ana Grande-Pérez Héctor Tejero Josep Gregori Josep Quer Juan I. Esteban Esteban Domingo Celia Perales

Lethal mutagenesis, or virus extinction produced by enhanced mutation rates, is under investigation as an antiviral strategy that aims at counteracting the adaptive capacity of viral quasispecies, and avoiding selection of antiviral-escape mutants. To explore lethal mutagenesis of hepatitis C virus (HCV), it is important to establish whether ribavirin, the purine nucleoside analogue used in ant...

Journal: :Journal of virology 2003
William E Severson Connie S Schmaljohn Ali Javadian Colleen B Jonsson

Except for ribavirin, no other antiviral drugs for treating hantaviral diseases have been identified. It is well established that ribavirin will inhibit the production of infectious Hantaan virus (HTNV); however, its mechanism of action is unknown. To characterize the inhibitory effect of ribavirin on HTNV, the levels of viral RNAs, proteins, and infectious particles were measured for 3 days po...

Journal: :hepatitis monthly 0
zaigham abbas department of medicine, the aga khan university hospital, karachi, pakistan; department of medicine, the aga khan university hospital, stadium road, karachi, pakistan. tel/fax: +92-214930051 ghiasun nabi tayyab postgraduate medical institute, lahore, pakistan mustafa qureshi department of medicine, the aga khan university hospital, karachi, pakistan mohammad sadik memon department of medicine, isra university hospital, hyderabad, india amna subhan department of medicine, the aga khan university hospital, karachi, pakistan tanzila shakir department of medicine, the aga khan university hospital, karachi, pakistan

conclusions more than one-quarter of treatment-experienced patients with hcv genotype 3 achieved svr after re-treatment with consensus interferon plus ribavirin. objectives we aimed to assess the efficacy and safety of cifn and ribavirin in non-responders and relapsers to pegylated interferon with ribavirin therapy. patients and methods this open-label investigator-initiated study included 44 p...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید